Satsuma Pharmaceuticals Inc (STSA) Stock Analyst Ratings
NASDAQ:STSA - Nasdaq - US80405P1075 - Common Stock - Currency: USD
ChartMill assigns a Buy % Consensus number of 76% to STSA. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 2.04. This target is 85.45% above the current price.
STSA was analyzed by 11 analysts. The buy percentage consensus is at 76. So analysts seem to be have mildly positive about STSA.
In the previous month the buy percentage consensus was at a similar level.
STSA was analyzed by 11 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2023-04-18 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2023-03-30 | Mizuho | Reiterate | Neutral |
| 2023-03-30 | HC Wainwright & Co. | Reiterate | Buy |
| 2022-11-15 | Mizuho | Downgrade | Buy -> Neutral |
| 2022-11-15 | SVB Leerink | Downgrade | Outperform -> Market Perform |
| 2022-11-15 | HC Wainwright & Co. | Maintains | Buy |
| 2022-10-10 | SVB Leerink | Upgrade | Market Perform -> Outperform |
| 2022-09-21 | HC Wainwright & Co. | Maintains | Buy |
| 2022-08-31 | Ladenburg Thalmann | Initiate | Buy |
| 2022-08-25 | JonesTrading | Initiate | Buy |
| 2022-05-13 | Mizuho | Maintains | Buy |
| 2021-06-22 | Mizuho | Upgrade | Neutral -> Buy |
| 2021-05-12 | SVB Leerink | Maintains | Market Perform |
| 2021-03-02 | Credit Suisse | Upgrade | Underperform -> Neutral |